Liminatus Pharma LIMN
NASDAQ LIMN
$3.90 +0.11 (+2.90%)
At close: Oct 2, 2026 · 4:00 PM EDT

Liminatus Pharma (LIMN) Return on Assets [ROA] (2025 - 2026)

Updated

Liminatus Pharma's Return on Assets [ROA] came in at -133.70% for Q2 2026, up 102.39 percentage points from the prior quarter.

Analysis

Liminatus Pharma (LIMN) Return on Assets [ROA] (2025 - 2026) Analysis & Trends

For FY2025, Liminatus Pharma's Return on Assets [ROA] was -104.94%.

  • Business Quant data shows LIMN's Return on Assets [ROA] at -236.09% (Q1 2026), -334.96% (Q4 2025) and -149.71% (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROA (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 20.64%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 10.47%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 4.65%
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn 2.45%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 28.37%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 9.10%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 9.29%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -6.13%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 2.14%
10 Liminatus Pharma 4.37 Mn 4.37 Mn - -133.70%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -133.70%
Mar 31, 2026 -236.09%
Dec 31, 2025 -334.96%
Sep 30, 2025 -149.71%
API Access

Liminatus Pharma Return on Assets [ROA] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-assets-%5Broa%5D&ticker=LIMN&period=max&api_key=YOUR_API_KEY